Company Overview
Sales
23
Cr
Growth: -2.6%
Profit after Tax
-9.72
Cr
Growth:
-6.9%
Micro Cap
58.9
Cr
P/S:
2.6x
Industry P/S: 3.2x
Fundamentals
| Sales (Cr) |
₹ 23 |
| Growth |
-2.6% |
| EBITDA |
-35.9% |
| P/S |
2.6x |
| Dividend |
0.0% |
| P/E |
-6.1x |
| Book Value |
₹ -12.1 |
| PEG Ratio |
2.4x |
| ROE |
35.7% |
| P/B |
N/A |
Shareholding Pattern
Institutions
Life Insurance Corporation Of India
3.36
%
Promoters
The Sri Krishna Trust Through Its Trustees Mr. Ajay G Piramal And Dr. (Mrs.) Swati A Piramal
33.1
%
Piramal Enterprises Limited
17.53
%
Ms. Nandini Piramal
1.49
%
Piramal Welfare Trust (Formerly Known As The Piramal Enterprise Executives Trust)
1.41
%
Others
Increase
Decrease
No change
Piramal Life Sciences Limited (PLSL) is an independent research-driven drug company incorporated in 2001, which was recently demerged from Piramal Healthcare Limited (Formerly known as Nicholas Piramal India Limited). PLSL was formerly the NCE R&D division of NPIL. PLSL has state-of-the-art R&D laboratories built over 200,000 square-feet of space in Mumbai, India and over 300 scientists engaged in drug discovery and development.
